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EDITORIAL COMMENT
Reversing Heart Failure With a
Ventricular Anchoring Device
Another Hope for Myopathic Mitral Regurgitation*
J. Eduardo Rame, MD
H eart failure due to left ventricular (LV) sys-tolic dysfunction remains highly prevalent,progressive in natural history, and prob-
lematic for patients hoping to survive with a good
quality of life. The anatomic and physiologic adapta-
tions in response to myocardial injury with ensuing
LV dysfunction include neurohumoral activation of
sympathetic and renin-angiotensin-aldosterone sys-
tems, along with counter-regulatory response of
natriuretic peptide systems; metabolic shifts adapt-
ing to increasing energetic demand; and LV chamber
dilatation. We evolved to incorporate these adapta-
tions to facilitate survival in the critical period of
acute exposure to risk. However, at least 2 of these
adaptations—neurohumoral activation and LV dilata-
tion—become maladaptive over the longer term.
Indeed, we are confident from the positive results of
many randomized clinical trials that blockade of
neurohumoral pathways improves heart failure, in
some instances achieving a high degree of myocardial
reverse remodeling, returning the LV cavity to near
normal end-systolic and end-diastolic dimensions.
Increasing end-systolic and end-diastolic LV di-
mensions is a hallmark of progressive, car-
diomyopathic failure, which is often accompanied by
secondary mitral regurgitation (MR). The increase in
LV volumes allows for maintenance of stroke volume
and, depending on the changes in myocardial stiff-
ness, could also maintain lower LV filling pressures.
However, LV dilatation comes with the bioenergetic
cost of increasing wall stress and myocardial oxygen
consumption, along with the increasing risk of pul-
monary venous congestion due to secondary MR of
myopathic origin. In the current era, device therapy
for heart failure due to cardiomyopathic LV systolic
dysfunction incorporates paradigms of resynchroni-
zation (cardiac resynchronization therapy), mechan-
ical unloading with ventricular assist devices, and
aortic counterpulsation. All of these have been
demonstrated to induce reverse remodeling of the LV
via multifaceted mechanisms, especially in the pa-
tients with a good clinical response (1–3).
In this issue of JACC: Basic to Translational Science,
it is in this context that the work by Saeed et al. (4)
should be considered. The soft robotic ventricular
assist device (SRVAD) is a free wall to septal brace
that effectively anchors the LV dimension while
actuating through an extrinsic force an increase in LV
ejection. By applying synchronized cyclic force
transmitted from the LV free wall to the interven-
tricular septum, the device provides dynamic
external compression and diastolic phase recoil back
to the “relaxed” curved configuration.
The preclinical data to investigate the effect of the
SRVAD using an adult swine model of acute LV sys-
tolic dysfunction with secondary MR induced by
intracoronary microsphere injections has demon-
strated elimination of the MR with significant in-
crease in LV fractional shortening at 5 and 30 min, an
increase in the median ejected stroke volume of 50%,
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and an increase in the LV developed pressure. With
the increased stroke volume, there is a significant
decrease in LV end-diastolic and left atrial pressure.
Finally, the electrocardiography-synchronized
augmentation of native pulsatile flow results in an
increase in pulse pressure and surplus hemodynamic
energy.
Although Saeed et al. (4) clearly demonstrate the
successful augmentation of LV output with reduction
of MR in this acute model, several questions remain.
First, what happens to the structure and function of
the LV, in the intermediate to long-term phase? Saeed
et al. intend to incorporate built-in pressure sensors
and test the device in a chronic animal model, but the
fundamental question of what physiologic changes
will result from sustained actuation of a ventricular
anchoring and compression device remains prescient.
Second, what are the longitudinal changes in neuro-
humoral activation within the acute, intermediate,
and long-term phases of this form of ventricular
support? If we expect, as is the case with pericardial
constriction, to have a net decrease in the myocardial
production and circulating levels of natriuretic pep-
tides, what should constitute the optimal neurohor-
monal antagonist therapy to work synergistically with
this mechanical paradigm of circulatory support?
Third, what are the acute and chronic changes in right
ventricular (RV) size and function, and the effects on
tricuspid regurgitation? Although we expect that a
decrease in MR and left atrial pressure will impact RV
afterload favorably, a critical question is: what effect,
if any, will the actuation of the device have on the RV
free wall to septal dimension? We know from study-
ing the effects of direct mechanical unloading with LV
assist devices that RV mechanics are affected with at
times a deleterious impact on RV function. Fourth, in
dyssynchronous heart failure, often accompanied by
clinically significant MR, can this device remain
effective, and what timing algorithms should be
considered to offset the septal to free wall delay?
Fifth, what is the potential for myocardial recovery
with adjunctive heart failure therapies of this me-
chanical platform? If the device can safely be main-
tained in low-support or nonactuated mode, can
future investigations demonstrate improved
contractility? Last, to target both clinical effective-
ness and maximize myocardial recovery, is there a
range for LV end-diastolic dimension and the degree
of MR that could be used to identify the patients who
could benefit the most after implantation of this car-
diac support device? We know from the ACORN trial
(5) that the CorCap fabric mesh device (Acorn Car-
diovascular, St. Paul, Minnesota) that was surgically
implanted for circumferential diastolic support
benefited patients the most who had a LV end-
diastolic dimension index in the range of 30 to
40 mm/m2. If the chronic preclinical models provide
variability in the degree of LV remodeling after
myocardial injury, it would be important to look for
this phenotype of maximal treatment response to the
SRVAD before translation toward clinical delivery.
Despite the need for clarity on these questions,
which will enhance our grasp of the physiology
relevant to this form of mechanically assisted heart
failure, the work by Saeed et al. (4) has undoubt-
edly introduced the question whether a single de-
vice paradigm can reverse myopathic MR while
sustaining ventricular output. Stay tuned. We can
only hope.
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